Company
Headquarters: Tübingen, Germany
Founded: 2000
Employees: 455
CEO: Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M.
€890.8 Million
EUR as of Jan. 1, 2026
US$1.05 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | €70.7 M |
| EBITDA | €208.8 M |
| Gross Profit TTM | €66.0 M |
| Profit Margin | 182.11% |
| Operating Margin | 573.04% |
| Quarterly Revenue Growth | -89.00% |
CureVac N.V. has the following listings and related stock indices.
Stock: FSX: 5CV wb_incandescent
Stock: NASDAQ: CVAC wb_incandescent
Stock: XETR: 5CV wb_incandescent
Stock: BMV: CVACN wb_incandescent
Founder(s): Ingmar Hoerr, Steve Pascolo, Florian von der Muelbe, Günther Jung and Hans- Georg Rammensee
Franz- Werner Haas (CEO)